Edition:
United Kingdom

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

2.01USD
22 Oct 2018
Change (% chg)

$0.13 (+6.91%)
Prev Close
$1.88
Open
$1.88
Day's High
$2.10
Day's Low
$1.88
Volume
9,818
Avg. Vol
30,979
52-wk High
$15.75
52-wk Low
$1.75

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  SMMT.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -- -- --
ROI: -- 0.21 14.27
ROE: -- 1.17 15.99

Japan Mitsubishi Corp to acquire 25 percent stake in Bangladesh LNG terminal

SINGAPORE Japan's Mitsubishi Corp on Friday said it has agreed to acquire 25 percent of Bangladesh's Summit Liquefied Natural Gas (LNG) terminal and plans to help develop an offshore receiving site in the South Asian country.

17 Aug 2018

Summit plunges 80 percent after muscle-wasting disorder drug fails

Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed a mid-stage study, wiping out nearly 80 percent of its market value.

27 Jun 2018

Summit plunges 80 percent after muscle-wasting disorder drug fails

Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed a mid-stage study, wiping out nearly 80 percent of its market value.

27 Jun 2018

UPDATE 2-Summit plunges 80 pct after muscle-wasting disorder drug fails

* Plummets 80 pct to touch record low (Adds details on trial, analyst comment)

27 Jun 2018

Summit Therapeutics to stop developing muscle-wasting disorder drug

June 27 Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed to meet the goals of a mid-stage study.

27 Jun 2018

BRIEF-Summit Therapeutics Files For Mixed Shelf Of Upto $225 Million

* SUMMIT THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source http://bit.ly/2jXftRN Further company coverage:

15 May 2018

Earnings vs. Estimates

No consensus analysis data available.